Sickle Cell Disease - Pipeline Review, H2 2015 Now Available at iData Insights Sickle Cell Disease - Pipeline Review, H2 2015 Summary Global Markets Direct s, Sickle Cell Disease Pipeline Review, H2 2015, provides an overview of the Sickle Cell Diseases therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sickle Cell Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Sickle Cell Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sickle Cell Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sickle Cell Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sickle Cell Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business
1
potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173362/sickle-celldisease-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173362/sickle-cell-disease-pipeline-review-h2-2015 Table of Contents
Introduction 7 Global Markets Direct Report Coverage 7 Sickle Cell Disease Overview 8 Therapeutics Development 9 Pipeline Products for Sickle Cell Disease - Overview 9 Pipeline Products for Sickle Cell Disease - Comparative Analysis 10 Sickle Cell Disease - Therapeutics under Development by Companies 11 Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes 15 Sickle Cell Disease - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Sickle Cell Disease - Products under Development by Companies 20 Sickle Cell Disease - Products under Investigation by Universities/Institutes 23 Sickle Cell Disease - Companies Involved in Therapeutics Development 24 Acceleron Pharma, Inc. 24 Acetylon Pharmaceuticals, Inc. 25 Addex Therapeutics Ltd 26 Advinus Therapeutics Ltd. 27 Alnylam Pharmaceuticals, Inc. 28 2
Bluebird bio, Inc. 29 Bristol-Myers Squibb Company 30 Complexa, Inc. 31 Daiichi Sankyo Company, Limited 32 Dilaforette AB 33 Emmaus Medical, Inc. 34 Errant Gene Therapeutics, LLC 35 Gamida Cell Ltd. 36 Gilead Sciences, Inc. 37 Global Blood Therapeutics, Inc. 38 Isis Pharmaceuticals, Inc. 39 Johnson & Johnson 40 La Jolla Pharmaceutical Company 41 Morphogenesis, Inc. 42 NKT Therapeutics, Inc. 43 Novartis AG 44 Orphagen Pharmaceuticals, Inc. 45 Pfizer Inc. 46 PharmaEssentia Corporation 47 Prolong Pharmaceuticals 48 ReveraGen BioPharma, Inc. 49 Sancilio & Company, Inc. 50 Sangamo BioSciences, Inc. 51 Sanofi 52 Sickle Cell Disease - Therapeutics Assessment 53 Assessment by Monotherapy Products 53
3
Assessment by Target 54 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 ACY-957 - Drug Profile 62 AIC-2011 - Drug Profile 63 AIC-6020 - Drug Profile 64 ALN-TMP - Drug Profile 65 Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders - Drug Profile 66 apixaban - Drug Profile 67 BB-305 - Drug Profile 69 CNTO-530 - Drug Profile 71 CordIn - Drug Profile 72 CXA-10 - Drug Profile 73 Didox - Drug Profile 74 Drugs to Inhibit PRMT5 for Sickle Cell Anemia - Drug Profile 78 DRX-194 - Drug Profile 79 EdX-17 - Drug Profile 80 GBT-440 - Drug Profile 81 Gene Therapy for Sickle Cell Anemia - Drug Profile 82 Gene Therapy for Sickle Cell Disease - Drug Profile 83 Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile 84 Gene Therapy to Activate Gamma Globin for Sickle Cell Disease - Drug Profile 85 glutamine - Drug Profile 86 HBI-002 - Drug Profile 88 HBI-137 - Drug Profile 89 4
LJPC-401 - Drug Profile 90 luspatercept - Drug Profile 91 NiCord - Drug Profile 92 NKTT-120 - Drug Profile 93 NM-96 - Drug Profile 94 panobinostat - Drug Profile 95 PB-04 - Drug Profile 101 pentosan polysulfate sodium - Drug Profile 103 PF-4447943 - Drug Profile 104 plerixafor - Drug Profile 105 PNQ-103 - Drug Profile 107 prasugrel hydrochloride - Drug Profile 108 Protein for Sickle Cell Disease - Drug Profile 111 regadenoson - Drug Profile 112 RN-1 - Drug Profile 114 RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile 115 Sanguinate - Drug Profile 116 SC-411 - Drug Profile 118 SCD-101 - Drug Profile 119 SCPF - Drug Profile 120 sevuparin sodium - Drug Profile 121 Small Molecule for Beta Thalassemia and Sickle Cell Anemia - Drug Profile 123 Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 124 Small Molecules for Sickle Cell Anemia - Drug Profile 125 Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 126
5
Small Molecules to Inhibit HDAC for Oncology and Sickle Cell Disease - Drug Profile 127 Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile 128 Stem Cell Therapy to Activate Beta Globin for Sickle Cell Disease - Drug Profile 129 Trichosic - Drug Profile 130 Verolone - Drug Profile 131 Sickle Cell Disease - Recent Pipeline Updates 133 Sickle Cell Disease - Dormant Projects 164 Sickle Cell Disease - Discontinued Products 166 Sickle Cell Disease - Product Development Milestones 167 Featured News & Press Releases 167 Appendix 173 Methodology 173 Coverage 173 Secondary Research 173 Primary Research 173 Expert Panel Validation 173 Contact Us 173 Disclaimer 174
Read More http://www.idatainsights.com/reports-landing-page.php?id=173362/sickle-cell-diseasepipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
6
ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
7